| Literature DB >> 33665452 |
Xiuping Sun1, Xuan Yu1, Ling Zhang1, Wenjie Zhao1, Manshi Wang1, Yu Zhang1, Xianglei Li1, Ran Gao1, Ludivine S Breger2, Sandra Dovero2, Gregory Porras2, Pierre-Olivier Fernagut2,3, Benjamin Dehay2, Erwan Bezard1,2, Chuan Qin1.
Abstract
Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE) is thought to enhance transgene expression of target genes delivered by adeno-associated viral (AAV) vectors. This study assessed the protein expression of α-synuclein, phosphorylated α-synuclein at Serine 129, extent of nigrostriatal degeneration as well as subsequent behavioral deficits induced by unilateral intranigral stereotactic injection in male adult C57BL/6J mice of an AAV2/9 expressing A53T human α-synuclein under the control of the synapsin promoter in presence or absence of the WPRE. The presence of WPRE enabled to achieve greater nigrostriatal degeneration and synucleinopathy which was concomitant with worsened forelimb use asymmetry. This work refines a mouse Parkinson's disease model in which anatomo-pathology is related to behavioral deficits.Entities:
Keywords: Mouse; Parkinson's disease; Synucleinopathy; Woodchuck hepatitis virus post-transcriptional regulatory element
Year: 2021 PMID: 33665452 PMCID: PMC7903312 DOI: 10.1016/j.heliyon.2021.e06302
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1α-Synuclein expression at striatal (A–C) and mesencephalic (D–F) levels 12 weeks after intranigral injection of AAV2/9-synapsin-synA53T (A,D) and AAV2/9-synapsin-synA53T-WPRE (B,E). Representative images (Scale bars: 1.0 mm for striatum, 0.5 mm for SNpc) and surface quantification of hα-syn immunostaining in striatum (A–C) and SNpc (D–F) are displayed. Higher magnification pictures are shown (Scale bar: 40 μm) below each representative image. Data are expressed as mean percentage ±SEM of n = 10 mice per group. ∗∗p < 0.0001, compared to non-injected side.
Figure 2TH expression at striatal (A–C) and mesencephalic (D–F) levels 12 weeks after intranigral injection of AAV2/9-synapsin-synA53T (A,D) and AAV2/9-synapsin-synA53T-WPRE (B,E). AAV2/9-synapsin-synA53T and AAV2/9-synapsin-synA53T-WPRE induced degeneration of dopaminergic neurons as assessed by analysis of optical density of striatal TH-positive terminals (representative images: A, B; quantification: C) and by stereological quantification of TH-positive cells in SNpc (representative images:D, E; quantification: F). Scale bar: 0.5 mm for SNpc and 1 mm for striatum. Higher magnification pictures are shown (Scale bar: 100 μm for straitum and 40 μm for SNpc) below each representative image. Data are expressed as mean ± SEM of 10 mice per group. ∗∗p < 0.01, ∗∗∗p < 0.0001 compared to non-injected side. ##p < 0.0001, compared to AAV2/9-synapsin-synA53T.
Figure 3Immunodetection of α-synuclein phosphorylated at serine 129 (pS129) at striatal (A–C) and mesencephalic (D–F) levels 12 weeks after intranigral injection of AAV2/9-synapsin-synA53T (A,D) and AAV2/9-synapsin-synA53T-WPRE (B,E). AAV2/9-synapsin-synA53T and AAV2/9-synapsin-synA53T-WPRE induced increase in pS129 in striatum (representative images: A,B; quantification: C) and SNpc (representative images: D,E; quantification: F) Scales: 1.0 mm for Striatum, 0.5 mm for SNpc. Higher magnification pictures are shown (Scale bar: 40 μm) below each representative image). Data are expressed as mean percentage ±SEM of n = 10 mice per group. ∗∗p < 0.001 compared to non-injected side. ###p < 0.001, compared to AAV2/9-synapsin-synA53T.
Figure 4Effect of AAV2/9-synapsin-synA53T and AAV2/9-synapsin-synA53T-WPRE on the challenging beam test (A–C) and forelimb asymmetry in the cylinder test (D–F) assessed 12 weeks after injection. Data are expressed as mean ± SEM of 10 mice per group. D) Difference between both sides in AAV2/9-synapsin-synA53T-WPRE animals achieved p = 0.0691.